Science Explorer Interactive view Map
Company · Waltham · United States

Deciphera Pharmaceuticals (United States)

deciphera.comROR OpenAlex
Research works
71
▲ 21% vs 2013–17
Citations
1.1k
15.8 per fractional work
Top-10% rate
9.6%
record average 16.5%
Open access
36%
world 28%

Not ranked overall: Deciphera Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 6.50× its world share, 10 worksBiochemistry, Geneti…Immunology and Microbiology: 2.77× its world share, 1 worksImmunology and Micro…Chemical Engineering: 3.41× its world share, 0 worksChemical EngineeringChemistry: 1.52× its world share, 1 worksChemistryComputer Science: 0.15× its world share, 0 worksComputer ScienceEngineering: 0.16× its world share, 1 worksEngineeringMedicine: 2.88× its world share, 16 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 6.5×. Every wedge is a field page.

Who are the top researchers at Deciphera Pharmaceuticals (United States)?

Ranked on the composite score, Daniel L. Flynn, B. Harrow and Yu Zhan lead among researchers whose main affiliation is Deciphera Pharmaceuticals (United States).

  1. 1 Daniel L. Flynn United States · #1,210,720 worldwide 53 citations · 27 works
  2. 2 B. Harrow United States · #1,239,490 worldwide 28 citations · 27 works
  3. 3 Yu Zhan United States · #1,585,105 worldwide 6 citations · 20 works
All ranked researchers at Deciphera Pharmaceuticals (United States)

Which keywords describe research at Deciphera Pharmaceuticals (United States)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: Prognostic Factors, Chemotherapy, Apoptosis, Cell Death, PET Imaging, Cancer Therapy, Imatinib Mesylate and Sunitinib.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 25 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 25 words, with their numbers
  1. Prognostic Factors5▲ 43×4 topics
  2. Chemotherapy4▲ 20×8 topics
  3. Apoptosis4▲ 41×5 topics
  4. Cell Death3▲ 50×3 topics
  5. PET Imaging3▲ 67×3 topics
  6. Cancer Therapy3▲ 19×6 topics
  7. Imatinib Mesylate3▲ 218×1 topic
  8. Sunitinib3▲ 400×1 topic
  9. Oxidative Stress3▲ 6.5×3 topics
  10. Cancer3▲ 7.5×12 topics
  11. Clinical Practice Guidelines3▲ 18×2 topics
  12. Endoplasmic Reticulum2▲ 318×1 topic
  13. Stress2▲ 23×1 topic
  14. Inflammation2▲ 3.8×9 topics
  15. Imaging2▲ 29×3 topics
  16. Radiotherapy2▲ 18×5 topics
  17. Osteosarcoma2▲ 138×1 topic
  18. Soft Tissue Sarcoma2▲ 121×1 topic
  19. Tumor Microenvironment2▲ 15×5 topics
  20. Pigmented Villonodular Synovitis2▲ 466×1 topic
  21. Synovial Chondromatosis2▲ 466×1 topic
  22. Proteasome Inhibitors2▲ 87×2 topics
  23. Gene Expression1▲ 8.4×4 topics
  24. Metabolism1▲ 8.3×4 topics
  25. Immunity1▲ 9.2×3 topics

Which research topics does Deciphera Pharmaceuticals (United States) publish most on?

By volume in 2022–2025: Gastrointestinal Tumor Research and Treatment, Endoplasmic Reticulum Stress and Disease, Sarcoma Diagnosis and Treatment and Musculoskeletal synovial abnormalities and treatments.

Gastrointestinal Tumor R…3Gastrointestinal Tumor Research and Treatment: 3 fractional worksEndoplasmic Reticulum Stress and Disease: 2 fractional worksSarcoma Diagnosis and Treatment: 2 fractional worksMusculoskeletal synovial…2Musculoskeletal synovial abnormalities and treatments: 2 fractional worksUbiquitin and proteasome pathways: 1 fractional worksBiochemical and Molecular Research: 1 fractional worksMultiple Myeloma Research and Treatments: 1 fractional worksGastric Cancer Management and Outcomes: 1 fractional worksCancer Immunotherapy and Biomarkers: 1 fractional worksMelanoma and MAPK Pathways: 1 fractional works
GastroenterologyCell BiologyPulmonary and Respiratory MedicineRheumatology3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Gastrointestinal Tumor Research and Treatment Gastroenterology 3 works
  2. 2 Endoplasmic Reticulum Stress and Disease Cell Biology 2 works
  3. 3 Sarcoma Diagnosis and Treatment Pulmonary and Respiratory Medicine 2 works
  4. 4 Musculoskeletal synovial abnormalities and treatments Rheumatology 2 works
  5. 5 Ubiquitin and proteasome pathways Molecular Biology 1 works
  6. 6 Biochemical and Molecular Research Molecular Biology 1 works
  7. 7 Multiple Myeloma Research and Treatments Hematology 1 works
  8. 8 Gastric Cancer Management and Outcomes Pulmonary and Respiratory Medicine 1 works
  9. 9 Cancer Immunotherapy and Biomarkers Oncology 1 works
  10. 10 Melanoma and MAPK Pathways Molecular Biology 1 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available35.9%not open64.1%

World: 28% of research is openly available.

with international co-authors17.4%domestic only82.6%

World: 19% is written across borders.

How has Deciphera Pharmaceuticals (United States)'s research output changed?

Output in 2018–2022 was 21% higher than in 2013–2017.

2005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Waltham

All research institutions in Waltham

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.